No immediate red flag; monitor for continued selling beyond these amounts or lack of reinvestment. Absence of buy signals, but no material negative catalyst implied.
VIR drugs
VIR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 23 $7.43entry
- T+1 · 9mo ago +27.73%α +26.99% · $9.49
- T+5 · 9mo ago +25.71%α +25.09% · $9.34
- T+20 · 8mo ago +18.98%α +22.92% · $8.84
- T+60 · 6mo ago +18.04%α +9.78% · $8.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple top executives at Vir Biotechnology, including the CEO, CFO, and CMO, sold shares worth over $220K in the past week, following a large block of stock awards totaling over 450,000 shares. The sales appear to be part of a planned divestiture after recent vesting, signaling routine post-award selling rather than a negative outlook.
Key Financial Metrics
Key Facts
- CEO Marianne De Backer sold 19,039 shares for $141,894; also received 285,000 shares via award (likely vesting).
- CFO Jason O'Byrne, CMO Mark Eisner, General Counsel Vanina de Verneuil, and CAO Brent Sabatini each sold between 1,829 and 4,445 shares, totaling $220K in sales over 2 days.
- All five executives received substantial stock awards on 2026-02-22 at $0 price, indicating vesting of prior grants.
- Sales occurred at $7.4528 per share, consistent with market price, suggesting pre-arranged 10b5-1 plans or routine post-vest diversification.
Financial Impact
$220,000 in insider sales; offset by $3.4M in newly vested shares (459,573 shares at $7.45)
Risk Factors
- Perception of lack of confidence if media spins sales negatively.
- Potential for follow-on selling if this is the start of broader divestment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (10 trades, 7d window) | cluster-VIR-1771978457278 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers